Issue Date | Title | Type | Author(s) |
2020 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma | Articulo | Sangro, B. (Bruno); Melero, I. (Ignacio); Wadhawan, S. (Samir); Finn, R.S. (Richard S.); Abou-Alfa, G.K. (Ghassan K.); Cheng, A.L. (Ann-Lii); Yau, T. (Thomas); Furuse, J. (Junji); Park, J.W. (Joong-Won); Boyd, Z. (Zachary); Tang, H.T. (Hao Tracy); Shen, Y. (Yun); Tschaika, M. (Marina); Neely, J. (Jaclyn); El-Khoueiry, A. (Anthony) |
2021 | CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis | Articulo | Kudo, M. (Masatoshi); Matilla, A. (Ana); Santoro, A. (Armando); Melero, I. (Ignacio); Cubillo-Gracián, A. (Antonio); Acosta-Rivera, M. (Mirelis); Choo, S.P. (Su-Pin); El-Khoueiry, A. (Anthony); Kuromatsu, R. (Ryoko); El-Rayes, B.F. (Bassel F.); Numata, K. (Kazushi); Itoh, Y. (Yoshito); Di-Costanzo, F. (Francesco); Crysler, O. (Oxana); Reig, M. (Maria); Shen, Y. (Yun); Neely, J. (Jaclyn); Tschaika, M. (Marina); Wisniewski, T. (Tami); Sangro, B. (Bruno) |
2020 | Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study | Articulo | Julien, K. (Karen); Leung, H.T. (Hiu Tung); Fuertes, C. (Carmen); Mori, M. (Megumi); Wang, M.J. (Miao-Jen); Teo, J. (Jocelyn); Weiss, L. (Lisa); Hamilton, S. (Sara); DiFebo, H. (Holly); Noh, Y.J. (Yoon-Jin); Galway, A. (Aralee); Koh, J. (Jane); Brutcher, E. (Edith); Zhao, H. (Huanyu); Shen, Y. (Yun); Tschaika, M. (Marina); To, Y.Y. (Yue-Yun) |
2023 | Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 | Articulo | El-Khoueiry, A. (Anthony); Trojan, J. (Jörg); Meyer, T. (Tim); Yau, T. (Thomas); Melero, I. (Ignacio); Kudo, M. (Masatoshi); Hsu, C. (Chiun); Kim, T.Y. (Tae-You); Choo, S.P. (Su-Pin); Kang, Y.K. (Yoon-Koo); Yeo, W. (W.); Chopra, A. (A.); Soleymani, S. (S.); Yao, J. (J.); Neely, J. (Jaclyn); Tschaika, M. (Marina); Welling, T.H. (T. H.); Sangro, B. (Bruno) |
2022 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial | Articulo | Yau, T. (Thomas); Park, J.W. (Joong-Won); Finn, R.S. (Richard S.); Cheng, A.L. (Ann-Lii); Mathurin, P. (Philippe); Edeline, J. (Julien); Kudo, M. (Masatoshi); Harding, J.J. (James J.); Merle, P. (Philippe); Rosmorduc, O. (Olivier); Wyrwicz, L. (Lucjan); Schott, E. (Eckart); Choo, S.P. (Su-Pin); Kate-Kelley, R. (Robin); Sieghart, W. (Wolfgang); Assenat, E. (Eric); Zaucha, R. (Renata); Furuse, J. (Junji); Abou-Alfa, G.K. (Ghassan K.); El-Khoueiry, A. (Anthony); Melero, I. (Ignacio); Begic, D. (Damir); Chen, G. (Gong); Neely, J. (Jaclyn); Wisniewski, T. (Tami); Tschaika, M. (Marina); Sangro, B. (Bruno) |